Clinical Research Directory
Browse clinical research sites, groups, and studies.
Oral Colloidal Silicon Dioxide Added to Routine Treatment for Acute Urticaria in the Emergency Department
Sponsor: Ankara Etlik City Hospital
Summary
The goal of this observational study is to learn whether adding a single oral dose of colloidal silicon dioxide, an enterosorbent, to routine emergency department treatment is associated with faster early improvement in adults with acute urticaria. The main question it aims to answer is: Is the change in urticaria activity over the first 2 hours different in patients who receive colloidal silicon dioxide in addition to intravenous pheniramine compared with patients who receive intravenous pheniramine alone? Treatment is chosen by the treating emergency physician as part of routine care, before patients are approached for the study. Participants are assessed before treatment and at 1 and 2 hours, and are contacted by telephone at 24 hours.
Official title: Early Outcomes With Adjunctive Oral Colloidal Silicon Dioxide for Acute Urticaria in the Emergency Department: A Prospective Observational Pilot Study
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
OBSERVATIONAL
Enrollment
70
Start Date
2026-08-24
Completion Date
2026-10-01
Last Updated
2026-10-08
Healthy Volunteers
No
Conditions
Interventions
Colloidal silicon dioxide
Single oral dose of 3 g colloidal (highly dispersed) silicon dioxide, a CE-marked enterosorbent medical device, suspended in 100-150 mL of water and taken at presentation, in addition to routine intravenous pheniramine. Use was decided by the treating emergency physician as part of routine care, not assigned by the study.
Locations (1)
Ankara Etlik City Hospital
Ankara, Turkey (Türkiye)